Previous close | 5.27 |
Open | 5.38 |
Bid | 5.26 x 100 |
Ask | 5.31 x 300 |
Day's range | 5.26 - 5.70 |
52-week range | 4.03 - 8.96 |
Volume | |
Avg. volume | 3,381,419 |
Market cap | 1.086B |
Beta (5Y monthly) | 1.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.07 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 14.00 |
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript May 6, 2024 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $-0.23. BCRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences: Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET. 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET. Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET. H.C. Wainwr
BioCryst Pharmaceuticals ( NASDAQ:BCRX ) First Quarter 2024 Results Key Financial Results Revenue: US$92.8m (up 35...